CAS NO: | 2108899-91-6 |
包装 | 价格(元) |
5mg | 电议 |
10mg | 电议 |
Cas No. | 2108899-91-6 |
化学名 | 2-[4-(4-chlorophenyl)-2-thiazolyl]hydrazone-cyclopentanone, monohydrochloride |
Canonical SMILES | ClC(C=C1)=CC=C1C2=CSC(N/N=C3CCCC\3)=N2.Cl |
分子式 | C14H14ClN3S o HCl |
分子量 | 328.3 |
溶解度 | ≤5mg/ml in ethanol;16mg/ml in DMSO;5mg/ml in dimethyl formamide |
储存条件 | Store at -20℃ |
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
产品描述 | CPTH2 is an inhibitor of HAT activity of Gcn5. Histone acetyltransferases (HATs) has been identified to add the acetyl group on the specific lysine of histone H3 and H4 N-termini, and such signatures are able to increase the accessibility of the underlying chromatin at specific genes or over vast regions of the genome. Gcn5p is a chimeric protein made up of a number of functional domains. In vitro: Previous study identified a novel molecule named CPTH2, which was selected based on its inhibitory effect on the growth of a gcn5Delta strain. This study indicated a specific chemical-genetic interaction between CPTH2 and HAT Gcn5p, suggesting that CPTH2 could inhibit the dependent functional network of Gcn5p. In addition, CPTH2 was found to be able to inhibit an in-vitro HAT reaction, which could be reverted by increasing concentration of histone H3 [1]. In vivo: In vivo, CPTH2 could decrease the acetylation of bulk histone H3 at the specific H3-AcK14 site [1]. Clinical trial: Up to now, CPTH2 is still in the preclinical development stage. Reference: |